Aminocaproic Acid Powder
NDC Package 55152-003-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Aminocaproic Acid powders is a medication used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This formulation utilizes a powder delivery system. Marketed by Sekisui Medical Co., Ltd., this product is identified by NDC 55152-003.

Identification & Billing

NDC Package Code
55152-003-01
Package Description
1 BAG in 1 DRUM / 50 kg in 1 BAG
Product Code
11-Digit Billing Format
55152000301

Clinical Specifications

Proprietary Name
Aminocaproic Acid
Non-Proprietary Name
Aminocaproic Acid
Substance Name
Aminocaproic Acid
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
Usage Information
This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This may cause serious bleeding after certain surgeries or in certain conditions (such as bleeding disorders, liver disease, cancer). Aminocaproic acid works by helping your blood clot normally. It belongs to a class of drugs known as antifibrinolytics.

Regulatory & Marketing

Labeler Name
Sekisui Medical Co., Ltd.
Product Type
Bulk Ingredient
Marketing Category
BULK INGREDIENT - A category specifying that a product is marketed as a bulk ingredient.
Start Marketing Date
03-07-1985
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 55152-003-01 identifies a specific commercial package of 1 bag in 1 drum / 50 kg in 1 bag of Aminocaproic Acid (UNFINISHED drug), a bulk ingredient labeled by Sekisui Medical Co., Ltd.. This powder is formulated for use and contains aminocaproic acid as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sekisui Medical Co., Ltd. on March 07, 1985. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to help control bleeding due to a condition where your blood does not clot the way it normally should (fibrinolysis). This may cause serious bleeding after certain surgeries or in certain conditions (such as bleeding disorders, liver disease, cancer). Aminocaproic acid works by helping your blood clot normally. It belongs to a class of drugs known as antifibrinolytics.

How is this Sekisui Medical Co., Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 55152000301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
55152-003-01
11-Digit CMS (5-4-2)
55152-0003-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.